Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders

REFERENCES

1. 1.↵
   2. Wingerchuk DM,
   3. Lennon VA,
   4. Pittock SJ, et al

   . Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–89 doi:10.1212/01.wnl.0000216139.44259.74 pmid:16717206

   Abstract/FREE Full Text
2. 2.↵
   2. Wingerchuk DM,
   3. Hogancamp WF,
   4. O'Brien PC, et al

   . The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107–14 doi:10.1212/WNL.53.5.1107 pmid:10496275

   Abstract/FREE Full Text
3. 3.↵
   2. Lennon VA,
   3. Wingerchuk DM,
   4. Kryzer TJ, et al

   . A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106–12 doi:10.1016/S0140-6736(04)17551-X pmid:15589308

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Wingerchuk DM,
   3. Lennon VA,
   4. Lucchinetti CF, et al

   . The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–15 doi:10.1016/S1474-4422(07)70216-8 pmid:17706564

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Wingerchuk DM,
   3. Banwell B,
   4. Bennett JL, et al

   ; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89 doi:10.1212/WNL.0000000000001729 pmid:26092914

   CrossRefPubMed
6. 6.↵
   2. Pittock SJ,
   3. Weinshenker BG,
   4. Lucchinetti CF, et al

   . Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964–68 doi:10.1001/archneur.63.7.964 pmid:16831965

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Pittock SJ,
   3. Lennon VA,
   4. Krecke K, et al

   . Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390–96 doi:10.1001/archneur.63.3.390 pmid:16533966

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Kim HJ,
   3. Paul F,
   4. Lana-Peixoto MA, et al

   ; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84:1165–73 doi:10.1212/WNL.0000000000001367 pmid:25695963

   Abstract/FREE Full Text
9. 9.↵
   2. Banker P,
   3. Sonni S,
   4. Kister I, et al

   . Pencil-thin ependymal enhancement in neuromyelitis optica spectrum disorders. Mult Scler 2012;18:1050–53 doi:10.1177/1352458511431730 pmid:22183933

   CrossRefPubMed
10. 10.↵
    2. Ito S,
    3. Mori M,
    4. Makino T, et al

    . “Cloud-like enhancement” is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009;66:425–28 doi:10.1002/ana.21753 pmid:19798642

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Long Y,
    3. Chen M,
    4. Zhang B, et al

    . Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid. J Neuroimmunol 2014;269:62–67 doi:10.1016/j.jneuroim.2014.02.006 pmid:24582827

    CrossRefPubMed
12. 12.↵
    2. Pekcevik Y,
    3. Izbudak I

    . Perivascular enhancement in a patient with neuromyelitis optica spectrum disease during an optic neuritis attack. J Neuroimaging 2015;25:686–87 doi:10.1111/jon.12198 pmid:25496413

    CrossRefPubMed
13. 13.↵
    2. Kim W,
    3. Park MS,
    4. Lee SH, et al

    . Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010;16:1229–36 doi:10.1177/1352458510376640 pmid:20685766

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Kim JE,
    3. Kim SM,
    4. Ahn SW, et al

    . Brain abnormalities in neuromyelitis optica. J Neurol Sci 2011;302:43–48 doi:10.1016/j.jns.2010.12.001 pmid:21236446

    CrossRefPubMed
15. 15.↵
    2. Kim W,
    3. Kim SH,
    4. Lee SH, et al

    . Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler 2011;17:1107–12 doi:10.1177/1352458511404917 pmid:21543554

    CrossRefPubMed
16. 16.↵
    2. McGraw CA,
    3. Swerdlow ML,
    4. Robbins MS

    . Acute reversible periependymal ventricular enhancement in neuromyelitis optica. Eur J Neurol 2012;19:57–58 doi:10.1111/j.1468-1331.2012.03696.x pmid:22577754

    CrossRefPubMed
17. 17.↵
    2. Cheng C,
    3. Jiang Y,
    4. Chen X, et al

    . Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions. BMC Neurol 2013;13:72 doi:10.1186/1471-2377-13-72 pmid:23819854

    CrossRefPubMed
18. 18.↵
    2. Pekcevik Y,
    3. Orman G,
    4. Lee IH, et al

    . What do we know about brain contrast enhancement patterns in neuromyelitis optica? Clin Imaging 2016;40:573–80 doi:10.1016/j.clinimag.2015.07.027 pmid:26615899

    CrossRefPubMed
19. 19.↵
    2. Weinshenker BG,
    3. Wingerchuk DM,
    4. Vukusic S, et al

    . Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566–69 doi:10.1002/ana.20770 pmid:16453327

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Wingerchuk DM,
    3. Weinshenker BG

    . Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60:848–53 doi:10.1212/01.WNL.0000049912.02954.2C pmid:12629245

    Abstract/FREE Full Text
21. 21.↵
    2. Keegan M,
    3. Pineda AA,
    4. McClelland RL, et al

    . Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143–46 doi:10.1212/WNL.58.1.143 pmid:11781423

    Abstract/FREE Full Text
22. 22.↵
    2. Wingerchuk DM

    . Neuromyelitis optica: effect of gender. J Neurol Sci 2009;286:18–23 doi:10.1016/j.jns.2009.08.045 pmid:19740485

    CrossRefPubMed
23. 23.↵
    2. Barnett Y,
    3. Sutton IJ,
    4. Ghadiri M, et al

    . Conventional and advanced imaging in neuromyelitis optica. AJNR Am J Neuroradiol 2014;35:1458–66 doi:10.3174/ajnr.A3592 pmid:23764723

    Abstract/FREE Full Text
24. 24.↵
    2. Argyriou AA,
    3. Makris N

    . Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008;118:209–17 doi:10.1111/j.1600-0404.2008.01002.x pmid:18336627

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Nema N,
    3. Verma A,
    4. Choudhary U, et al

    . Ocular oscillations and transient oscillopsia in neuromyelitis optica. J Neurol Res 2014;4:146–50
26. 26.↵
    2. Tahara M,
    3. Ito R,
    4. Tanaka K, et al

    . Cortical and leptomeningeal involvement in three cases of neuromyelitis optica. Eur J Neurol 2012;19:e47–e48 doi:10.1111/j.1468-1331.2012.03667.x pmid:22507460

    CrossRefPubMed
27. 27.↵
    2. Iorio R,
    3. Damato V,
    4. Mirabella M, et al

    . Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. J Neurol 2013;260:2396–402 doi:10.1007/s00415-013-6997-9 pmid:23793787

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Waters PJ,
    3. McKeon A,
    4. Leite MI, et al

    . Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665–71; discussion 669 doi:10.1212/WNL.0b013e318248dec1 pmid:22302543

    Abstract/FREE Full Text
29. 29.↵
    2. Nicchia GP,
    3. Nico B,
    4. Camassa LM, et al

    . The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 2004;129:935–45 doi:10.1016/j.neuroscience.2004.07.055 pmid:15561409

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Vincent T,
    3. Saikali P,
    4. Cayrol R, et al

    . Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181:5730–37 doi:10.4049/jimmunol.181.8.5730 pmid:18832732

    Abstract/FREE Full Text
31. 31.↵
    2. Levy LM

    . Exceeding the limits of the normal blood-brain barrier: quo vadis gadolinium? AJNR Am J Neuroradiol 2007;28:1835–36 pmid:17898191

    FREE Full Text
32. 32.↵
    2. Bradl M,
    3. Lassmann H

    . Experimental models of neuromyelitis optica. Brain Pathol 2014;24:74–82 doi:10.1111/bpa.12098 pmid:24345221

    CrossRefPubMed
33. 33.↵
    2. Takahashi T,
    3. Fujihara K,
    4. Nakashima I, et al

    . Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235–43 doi:10.1093/brain/awm062 pmid:17449477

    Abstract/FREE Full Text
34. 34.↵
    2. Sato DK,
    3. Callegaro D,
    4. de Haidar Jorge FM, et al

    . Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. Ann Neurol 2014;76:305–09 doi:10.1002/ana.24208 pmid:24977390

    CrossRefPubMed
35. 35.↵
    2. Jarius S,
    3. Franciotta D,
    4. Paul F, et al

    . Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010;7:52 doi:10.1186/1742-2094-7-52 pmid:20825655

    CrossRefPubMed
36. 36.↵
    2. Nishiyama S,
    3. Ito T,
    4. Misu T, et al

    . A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009;72:1960–61 doi:10.1212/WNL.0b013e3181a82621 pmid:19487655

    FREE Full Text
37. 37.↵
    2. Bergamaschi R,
    3. Ghezzi A

    . Devic's neuromyelitis optica: clinical features and prognostic factors. Neurol Sci 2004;25(suppl 4):S364–67 doi:10.1007/s10072-004-0342-0 pmid:15727235

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Lana-Peixoto MA

    . Devic's neuromyelitis optica: a critical review. Arq Neuropsiquiatr 2008;66:120–38 doi:10.1590/S0004-282X2008000100034 pmid:18392436

    CrossRefPubMed
39. 39.↵
    2. Jarius S,
    3. Ruprecht K,
    4. Wildemann B, et al

    . Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14 doi:10.1186/1742-2094-9-14 pmid:22260418

    CrossRefPubMed
40. 40.↵
    2. Jiao Y,
    3. Fryer JP,
    4. Lennon VA, et al

    . Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013;81:1197–204 doi:10.1212/WNL.0b013e3182a6cb5c pmid:23997151

    Abstract/FREE Full Text
41. 41.↵
    2. Bonnan M,
    3. Cabre P

    . Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012;2012:787630 doi:10.1155/2012/787630 pmid:22474589

    CrossRefPubMed